Table 3.

Reasons for discontinuation of baricitinib in the BSRBR-RA

Reason for discontinuation	n	%
6-month follow-up
Lack of efficacy	14	24.6
Adverse events	36	63.2
Other	7	12.3
12-month follow-up
Lack of efficacy	8	25.0
Adverse events	20	62.5
Other	4	12.5

A total of 59 patients with at least one recorded follow-up discontinued baricitinib by the 6-month follow-up and 34 patients with at least one recorded follow-up discontinued baricitinib by the 12-month follow-up; two patients had missing data at the 6-month follow-up and two patients had missing data at the 6-month follow-up.

n: number of patients with reported reason.